Fibrate: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
== Fibrate == | |||
[[File:Fenofibrate_structure.svg|thumb|right|Chemical structure of Fenofibrate]] | |||
'''Fibrates''' are a class of [[amphipathic carboxylic acids]] used primarily as [[lipid-lowering agents]]. They are particularly effective in reducing [[triglyceride]] levels and are also used to increase [[high-density lipoprotein]] (HDL) cholesterol levels. Fibrates are often prescribed to patients with [[dyslipidemia]], especially those with elevated triglycerides and low HDL cholesterol. | |||
== | == Mechanism of Action == | ||
[[File:PPAR-diagram.png|thumb|left|Diagram of PPAR activation]] | |||
Fibrates exert their effects by activating the [[peroxisome proliferator-activated receptor alpha]] (PPARα), a type of nuclear receptor. Activation of PPARα leads to increased expression of genes involved in fatty acid oxidation, lipoprotein metabolism, and [[apolipoprotein]] synthesis. This results in decreased triglyceride levels, increased HDL cholesterol, and a modest reduction in [[low-density lipoprotein]] (LDL) cholesterol. | |||
== | == Clinical Uses == | ||
Fibrates are primarily used to treat hypertriglyceridemia and mixed dyslipidemia. They are particularly beneficial in patients with metabolic syndrome or [[type 2 diabetes mellitus]], where triglyceride levels are often elevated. Fibrates can be used alone or in combination with other lipid-lowering agents such as [[statins]]. | |||
Fibrates | |||
== | == Common Fibrates == | ||
== | === Fenofibrate === | ||
[[File: | |||
[[File:Fenofibrate_structure.svg|thumb|right|Chemical structure of Fenofibrate]] | |||
Fenofibrate is one of the most commonly prescribed fibrates. It is used to reduce cholesterol levels in patients at risk of cardiovascular disease. | |||
=== Clofibrate === | |||
[[File:Clofibrate.svg|thumb|left|Chemical structure of Clofibrate]] | |||
Clofibrate was one of the first fibrates developed but is less commonly used today due to concerns about its safety profile. | |||
=== Bezafibrate === | |||
[[File:Bezafibrate.svg|thumb|right|Chemical structure of Bezafibrate]] | |||
Bezafibrate is used to treat hyperlipidemia and has a broad spectrum of action on lipid parameters. | |||
=== Ciprofibrate === | |||
[[File:Ciprofibrate.svg|thumb|left|Chemical structure of Ciprofibrate]] | |||
Ciprofibrate is another fibrate used to manage lipid disorders, particularly in patients with high triglyceride levels. | |||
=== Choline Fenofibrate === | |||
[[File:Choline_fenofibrate.svg|thumb|right|Chemical structure of Choline Fenofibrate]] | |||
Choline fenofibrate is a newer formulation designed to improve the bioavailability of fenofibrate. | |||
=== Clinofibrate === | |||
[[File:Clinofibrate.svg|thumb|left|Chemical structure of Clinofibrate]] | |||
Clinofibrate is used in some countries for the treatment of hyperlipidemia. | |||
=== Aluminium Clofibrate === | |||
[[File:Aluminium_clofibrate.svg|thumb|right|Chemical structure of Aluminium Clofibrate]] | |||
Aluminium clofibrate is a derivative of clofibrate, used in certain formulations. | |||
== Side Effects == | |||
Common side effects of fibrates include gastrointestinal disturbances, such as nausea and abdominal pain. Muscle pain and weakness can occur, particularly when fibrates are used in combination with statins. Rarely, fibrates can cause liver dysfunction and gallstones. | |||
== Related Pages == | |||
* [[Statin]] | * [[Statin]] | ||
* [[Cholesterol]] | * [[Cholesterol]] | ||
* [[Triglyceride]] | * [[Triglyceride]] | ||
* [[ | * [[Lipoprotein]] | ||
* [[Peroxisome proliferator-activated receptor]] | |||
[[Category:Hypolipidemic agents]] | [[Category:Hypolipidemic agents]] | ||
[[Category: | [[Category:Carboxylic acids]] | ||
Latest revision as of 14:18, 21 February 2025
Fibrate[edit]
Fibrates are a class of amphipathic carboxylic acids used primarily as lipid-lowering agents. They are particularly effective in reducing triglyceride levels and are also used to increase high-density lipoprotein (HDL) cholesterol levels. Fibrates are often prescribed to patients with dyslipidemia, especially those with elevated triglycerides and low HDL cholesterol.
Mechanism of Action[edit]
Fibrates exert their effects by activating the peroxisome proliferator-activated receptor alpha (PPARα), a type of nuclear receptor. Activation of PPARα leads to increased expression of genes involved in fatty acid oxidation, lipoprotein metabolism, and apolipoprotein synthesis. This results in decreased triglyceride levels, increased HDL cholesterol, and a modest reduction in low-density lipoprotein (LDL) cholesterol.
Clinical Uses[edit]
Fibrates are primarily used to treat hypertriglyceridemia and mixed dyslipidemia. They are particularly beneficial in patients with metabolic syndrome or type 2 diabetes mellitus, where triglyceride levels are often elevated. Fibrates can be used alone or in combination with other lipid-lowering agents such as statins.
Common Fibrates[edit]
Fenofibrate[edit]
Fenofibrate is one of the most commonly prescribed fibrates. It is used to reduce cholesterol levels in patients at risk of cardiovascular disease.
Clofibrate[edit]
Clofibrate was one of the first fibrates developed but is less commonly used today due to concerns about its safety profile.
Bezafibrate[edit]
Bezafibrate is used to treat hyperlipidemia and has a broad spectrum of action on lipid parameters.
Ciprofibrate[edit]
Ciprofibrate is another fibrate used to manage lipid disorders, particularly in patients with high triglyceride levels.
Choline Fenofibrate[edit]
Choline fenofibrate is a newer formulation designed to improve the bioavailability of fenofibrate.
Clinofibrate[edit]
Clinofibrate is used in some countries for the treatment of hyperlipidemia.
Aluminium Clofibrate[edit]
Aluminium clofibrate is a derivative of clofibrate, used in certain formulations.
Side Effects[edit]
Common side effects of fibrates include gastrointestinal disturbances, such as nausea and abdominal pain. Muscle pain and weakness can occur, particularly when fibrates are used in combination with statins. Rarely, fibrates can cause liver dysfunction and gallstones.
